That’s why Amgen ( AMGN) wants to reduce the number of shots needed. The company is developing an obesity drug called ...

Amgen's growth engine and Pfizer's value appeal pull in opposite directions, and the valuation gap between them is wider than ...

Amgen's Imdelltra has shown that it can significantly reduce the risk of death in patients who have extensive-stage small ...

Amgen (AMGN) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock. Over ...

Icelandic genetics helped shape MariTide, Amgen’s investigational obesity treatment now being tested in multiple Phase 3 ...

With the first Phase 3 data expected for Amgen’s MariTide next year, analysts are looking for evidence that the GLP-1 ...

The study tracked 544,103 adults with prior statin use over a period of up to four years in routine clinical care.

Amgen has raised its payout every year since 2011, yet the pace of those raises is cooling just as patent cliffs and drug ...

Amgen beat Wall Street's top- and bottom-line expectations late Tuesday, but there were puts and takes across the board.

Amgen Inc. AMGN shares are trading close to its 52-week high on Wednesday after the company reported better-than-expected ...

Amgen (NasdaqGS:AMGN) announced a new collaboration with the National Organization for Rare Disorders to speed rare ...

Amgen on Tuesday said third-quarter sales rose 8%, led by demand for cholesterol drug Repatha and newer medicines Imdelltra ...